

Drug Delivery in Cancer

Part I: Technologies & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

September 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 470 publications include 28 books (5 as editor+ 23 as author) and 50 commercial reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Edited books include "Drug Delivery Systems" (1st ed Humana/Springer 2008; 2nd ed 2014) and "Drug Delivery to the Central Nervous System" (Humana/Springer, 2010). As an author, his recent books include "Handbook of Nanomedicine" (Springer/Humana 2008; Chinese edition, Peking University Press 2011; 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical industry Press 2016, 2nd ed Springer 2017), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer, 2014). He has edited "Applied Neurogenomics" (Springer 2015).

A B O U T T H I S R E P O R T

The original report on Drug Delivery in Cancer by the author was published by Decision Resources Inc in 2000 as an enlargement of the chapter on this topic in his report on Drug Delivery Technologies (1998), which was also published by Decision Resources. The second edition was published at Jain PharmaBiotech in 2003 and has been constantly updated and rewritten since then.

**September 2017 (first edition published in 2000)
Copyright © 2017 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	19
1. Introduction to cancer therapy	21
Molecular biology of cancer	21
Cell cycle and cancer	21
<i>Apoptosis in cancer</i>	22
<i>Autophagy</i>	22
<i>Cell division and mitotic spindles</i>	23
<i>PD-1 Pathway</i>	23
<i>DNA damage, repair and cancer</i>	24
<i>Mechanism of DNA damage in Fanconi anemia leading to leukemia</i>	24
Cancer metabolism and energy status in relation to growth.....	24
<i>Amino acids and cancer</i>	24
<i>AMP-activated protein kinase</i>	25
<i>Cancer therapeutics that target metabolism.</i>	25
Cancer dormancy and relapse.....	26
Chromosomes and cancer	26
<i>Aneuploidy</i>	26
<i>Chromosomal instability</i>	27
<i>Telomeres and cancer</i>	27
Genes and cancer	28
<i>Accumulation of random mutations</i>	28
<i>Oncogenes</i>	28
<i>Role of Bub 1 gene in cell division</i>	29
<i>Tumor Suppressor Genes</i>	29
Hallmarks of cancer.....	30
Invasion and metastases	31
<i>Tumor suppressor genes and metastases</i>	32
Methylation and cancer.....	32
Oxidative stress and cancer.....	33
RNA and cancer	33
<i>Anticancer treatments based on RNA regulation of genes</i>	33
<i>Role of microRNAs in cancer</i>	33
Stem cells and cancer.....	34
Self-sufficiency of tumor proliferation	35
Therapeutic implications of apoptosis in cancer.....	35
Tumor angiogenesis	37
<i>Pathomechanism of angiogenesis</i>	37
<i>Role of VEGF in angiogenesis</i>	39
<i>Matrix stiffness-mediated angiogenesis in tumors</i>	39
Cancer biomarkers.....	39
Molecular imaging of cancer	40
Cancer genomics.....	40
Gene expression profiling in cancer	40
Cancer proteomics	41
Limitations of genomics and proteomics for understanding cancer	41
Cancer microenvironment.....	41
Epidemiology of cancer.....	42
Current management of cancer.....	42
Anticancer drugs.....	43
<i>Limitations of cancer chemotherapy</i>	43
Biological therapies for cancer	44
Radiotherapy.....	44
<i>Brachytherapy</i>	44
Ideal anticancer agent.....	44
Surgery	44
Basics of drug delivery in cancer	45
Role of mechanical forces in tumor growth and delivery of therapy	45
Methods of assessing drug delivery in cancer	45
Positron emission tomography (PET)	45
Historical landmarks in cancer drug delivery	46
2. Innovative treatments for cancer	47
Introduction	47
Selective estrogen receptor modulators	48
Antiangiogenic strategies for cancer	49
Development of antiangiogenic therapies	49

Classification of antiangiogenic agents	50
Examples of antiangiogenic agents	51
<i>ACE-041</i>	51
<i>Angiopoietin-2 as a target</i>	51
<i>Chemotherapy at lower than maximum tolerated dose</i>	51
<i>Galectin-3 as a target for inhibiting angiogenesis</i>	52
<i>Inhibitors of endothelial proliferation</i>	52
<i>Inducers of apoptosis of endothelial cells of tumor vessels</i>	52
<i>Lodamin</i>	53
<i>Matrix metalloproteinase inhibitors</i>	53
<i>Monoclonal antibodies with vasculostatic properties</i>	54
<i>PPARα agonists</i>	55
<i>Rapalogues as antiangiogenic agents</i>	55
<i>VEGF Trap</i>	56
Agents that decrease the permeability of tumor blood vessels	56
Antiangiogenic agents in clinical trials	56
Antiangiogenic therapy resistance	57
Combination of antiangiogenic with cytotoxic therapy	57
Antiangiogenic therapy for hematological malignancies	57
Bacterial anticancer agents	58
Tumor-targeted bacteria	59
<i>Bacterial protein for targeted delivery of liposomal cancer drugs</i>	59
<i>Genetically modified bacteria as anticancer agents</i>	59
<i>Live bacteria for delivering radioactive anticancer agents</i>	60
<i>Synchronized cycles of bacterial lysis with delivery of chemotherapy</i>	61
<i>Genetically altered strains of Salmonella as anticancer drug vectors</i>	61
Inactivated but metabolically active bacteria	62
Bacterial toxins targeted to tumors	62
<i>Immunotoxins</i>	62
<i>Escherichia Coli toxins</i>	62
<i>Engineered anthrax toxin</i>	63
<i>Recombinant fusion toxins</i>	63
Type III secretion systems	65
Induction of apoptosis in cancer by bacterial proteins	65
Induction of immune response by bacteriolytic therapy	65
Epigenetic targets for anticancer therapy	66
Innovations in cell therapy for cancer	66
Stem cell transplantation for cancer	67
Cancer drug/gene delivery by mesenchymal stem cells	67
Cancer immunotherapy	68
Cytokines	68
Epigenetic modulators and cancer immunotherapies	69
STING activation and antitumor immunity	71
Cancer vaccines	71
<i>5T4 as a target for cancer immunotherapy</i>	72
<i>Adoptive cell therapy</i>	72
<i>Antigen-specific cancer vaccines</i>	75
<i>Carcinoembryonic antigen-based vaccines</i>	76
<i>Carbohydrate-based cancer vaccines</i>	76
<i>Dendritic cells for cancer vaccination</i>	76
<i>Hybrid cell vaccination</i>	78
<i>SMART vaccines</i>	79
<i>Salmonella-based oral vaccine delivery</i>	79
<i>Tumor cell vaccines</i>	79
<i>Vaccines that simultaneously target different cancer antigens</i>	80
<i>Vaccines based on multiple tumor-associated peptides</i>	80
<i>Vaccine for cancer based on antimalaria protein</i>	81
Cancer Vaccine Consortium	81
Chemoimmunotherapy	81
Concluding remarks about cancer vaccines	82
Targeted delivery of peptides to tumor-associated macrophages	82
Targeting cancer stem cells	82
Monoclonal antibodies	83
Murine MAbs	83
Humanized MAbs	83
Actions and uses of MAbs in cancer	84
Targeted antibody-based cancer therapy	85
<i>Antibody-cytokine fusion proteins</i>	85
<i>Antibody ARGX-115 for targeting immunosuppressive effect of Tregs</i>	85
<i>Antibody J591 for targeted delivery of anticancer therapy</i>	85
<i>Anti-Thomsen-Friedenreich antigen MAb</i>	85

<i>Combining MAbs with anti-CD55 antibody</i>	86
<i>MAbs targeted to alpha fetaprotein receptor</i>	86
<i>MAbs that target angiogenesis</i>	86
MAbs for immune activation	87
Delivery of cancer therapy with MAbs	87
Antibody-directed enzyme prodrug therapy	88
Chemically programmed antibodies	88
Combining diagnostics with therapeutics based on MAbs	89
Radiolabeled antibodies for detection and targeted therapy of cancer	89
Other innovations for administration of antibodies	92
<i>Bispecific antibodies</i>	92
<i>Trifunctional antibodies</i>	93
<i>Tetravalent bispecific antibodies</i>	93
<i>Immunotoxins</i>	93
<i>Immunoliposomes</i>	94
<i>Combined use of MAbs and cytokines</i>	94
<i>huHMFG1-huDNase I</i>	95
<i>MAbs that selectively target cancer</i>	95
NanoMAbs for targeting cancer	95
Advantages and limitations of MAbs for cancer therapy	96
Antibody-drug conjugates	97
<i>Kadcyla</i>	98
<i>Adcetris</i>	98
Antibody-enzyme conjugates	99
Current and future trends in antibody-based cancer drugs	99
Innovative methods of radiation delivery	99
Image-guided ultrasound technology for delivery of radiation	99
Respiratory gating technology for radiation therapy	99
Positron therapy	100
Boron neutron capture therapy	100
<i>Application of drug delivery systems to BNCP</i>	101
<i>Use of nanotechnology to enhance BNCT</i>	102
Ion channels and transporters in cancer	102
Irreversible electroporation	103
Methods to overcome multidrug resistance (MDR)	103
Mechanism of MDR	103
<i>MDR-associated protein gene</i>	104
<i>P-glycoprotein-mediated MDR</i>	104
Strategies for overcoming MDR	104
<i>Blocking the action of P-glycoprotein</i>	104
<i>Combination of targeted drugs with different specificities</i>	105
<i>Enzyme Catalyzed Therapeutic Activation</i>	105
<i>Inhibition of DNA repair</i>	105
<i>Iron chelators that overcomes resistance to chemotherapeutics</i>	106
<i>Liposome formulation of anticancer drugs</i>	106
<i>Modification of the chemical structure of the anticancer drug</i>	107
<i>Managing resistance to antiapoptotic action of anticancer agents</i>	107
<i>Modulation of SPARC expression</i>	107
<i>Nitric oxide inducers</i>	107
<i>Proton pump inhibitors</i>	108
<i>Repression of Prohibitin1 in drug-resistant cancer cells</i>	108
Targeted cancer therapies	108
Targeting cellular pathways	108
Targeting antigens in virus-associated cancer	109
Targeting the IGF-I receptor	109
Targeting Mcl-1 protein	110
Targeting mitochondrial membranes	110
Targeting tumor lymphatics	111
<i>LyP-1 for targeting tumor lymphatics</i>	111
Targeting tyrosine kinase receptors	112
<i>Inhibitors of bcr-abl tyrosine kinase</i>	112
<i>Inhibition of multiple tyrosine kinases</i>	112
<i>Inhibitors of ErbB tyrosine kinase</i>	112
Targeting the Hedgehog signaling pathway	113
Targeting caspase-8	114
Targeting metallodrugs to tumor cells	114
Targeting oncogenes	114
Targeting miRNA for cancer therapeutics	115
Targeting the transferrin receptor-mediated endocytosis pathway	115
Targeted anticancer therapies based on the Rad51 promoter	116
Targeting cancer stem cells	116

Targeting glycolytic pathway in cancer.....	117
Targeting glycoproteins	118
<i>Tagging cancer with modified sugars</i>	118
<i>Anticancer agents based on glycobiology</i>	118
<i>Targeting cell surface glycoproteins</i>	118
<i>Biofusion for targeted cancer therapy</i>	119
Targeting knottin peptides	119
Tarveda's Pentarin platform for targeted drug conjugates	120
Enhancing the effects of radiation and chemotherapy	120
Sensitizing and enhancing agents for chemotherapy.....	120
<i>CoFactor to enhance the efficacy of chemotherapy</i>	120
<i>Enzyme-enhanced chemotherapy</i>	121
<i>Resveratrol and quercetin for cardioprotection against chemotherapy</i>	121
<i>Tesmiflifen for chemosensitization</i>	121
Sensitizing agents for radiotherapy	122
<i>IPdR</i>	122
<i>Ultrasound for enhancing response to radiation</i>	122
Manipulation of tumor oxygenation	123
<i>Hypoxia-based methods to enhance chemotherapy and radiotherapy</i>	123
<i>Hyperbaric oxygen and radiation</i>	124
<i>HIF-1 antagonists to enhance radiotherapy</i>	124
<i>Nonsteroidal antiinflammatory drugs enhance tumor radiosensitivity</i>	124
<i>ONCONASE as radiosensitivity enhancer</i>	124
Hyperthermia and chemotherapy/radiation therapy.....	125
<i>Techniques for hyperthermia</i>	125
<i>Trimodality therapy: radiation, chemotherapy, and hyperthermia</i>	125
Photodynamic therapy	126
<i>Photochemical internalization</i>	128
Thermal combination with focused ultrasound for drug delivery to tumors.....	128
Novel anticancer agents	129
Anti-EphA2 antibodies	129
Antioxidants	129
Bristollicin	129
Agents disrupting folate metabolism.....	130
<i>Pemetrexed</i>	130
Cell cycle inhibitors	130
Cytotoxic ribonucleases	131
DNA hypomethylating agents	131
Histone-based cancer therapy	131
<i>Histone deacetylase inhibitors</i>	132
<i>Modulation of p300/CBP histone acetyltransferase activity</i>	132
<i>Simulation of endogenous histone for anticancer therapy</i>	133
HSP90 inhibitors	133
Ion channel blockers	134
<i>IOT-101</i>	134
<i>Endovion</i>	134
LPAAT- β inhibitors.....	134
Modulation of pyruvate kinase M2	135
Modulators of protein ubiquitination	135
P13-kinase inhibitors.....	135
PARP inhibitors	135
<i>Targeted destruction of BRCA2 deficient tumors by PARP inhibitors</i>	136
<i>Companies developing and commercializing PARP inhibitors</i>	136
Prodrugs.....	137
<i>Enzyme-activated prodrugs</i>	137
<i>Ascorbic acid as a prodrug for cancer</i>	137
<i>Prolarix</i>	138
Procaspase-3 activation	138
Protein kinase G activation.....	138
Proteasome inhibitors.....	139
Recombinant human insulin-like growth factor binding protein-3.....	139
Second generation nucleosides	139
Targeting cancer metabolism.....	140
Targeting topoisomerase IB	140
Telomerase inhibitors	141
Therapeutic strategies based on the P53 pathway	141
Therapeutic strategies based on molecular mechanisms.....	142
<i>Checkpoint activation as a strategy against cancer</i>	142
<i>Deletion-specific targeting for cancer therapy</i>	143
<i>In vivo models for molecularly anticancer drugs</i>	143
<i>Repair-blocking drugs for enhancing effect of chemotherapy</i>	143

<i>Tumor targeting fields</i>	144
<i>Targeting mTOR signaling defects</i>	144
Combining novel anticancer approaches.....	144
Personalized therapy of cancer	145
Challenges of cancer classification.....	148
Design of future cancer therapies.....	148
Personalized drug development in oncology	149
<i>Role of molecular imaging</i>	149
<i>Role of molecular imaging in targeted cancer therapy</i>	150
<i>Screening for personalized anticancer drugs</i>	150
<i>Targeting pathways for personalized cancer therapy</i>	150
3. Drug delivery systems for cancer	152
Introduction	152
Routes of drug delivery in cancer	152
Intravenous delivery systems for cancer therapy	153
<i>Intravenous versus oral ascorbate for treatment of cancer</i>	154
Subcutaneous injection of anticancer agents	154
Oral delivery of anticancer agents	154
<i>5-FU combined with eniluracil</i>	156
<i>Cyclin D-dependent CDK4 and CDK6 inhibitors</i>	156
<i>High dose administration of calcitriol</i>	156
<i>Oral fluoropyrimidines</i>	157
<i>Oral gefitinib vs intravenous docetaxel</i>	157
<i>Oral paclitaxel</i>	158
<i>Oral satraplatin</i>	158
<i>Oral UFT</i>	158
<i>Oral PXD101</i>	159
Transdermal drug delivery	159
<i>Delivery of the photosensitizer drug δ-amino levulinic acid</i>	159
<i>Nanoemulsion-based delivery of caffeine for skin cancer</i>	159
<i>Transdermal delivery of methotrexate</i>	160
<i>Transdermal nitroglycerine for prostate cancer</i>	160
<i>Transdermal delivery of peptide cancer vaccines</i>	160
<i>Intradermal delivery of cancer vaccines by adenoviral vectors</i>	160
Pulmonary delivery of anticancer agents	161
Regional intra-arterial delivery of chemotherapy	161
Gas embolotherapy of tumors.....	162
Drug delivery to lymph nodes.....	162
Intraperitoneal macrophages as drug delivery vehicle.....	163
Challenges of cancer drug delivery	163
Tumor blood vessel pore barrier to drug delivery	163
Improvement of drug transport in tumors	163
Delivery of anticancer drugs to nuclear targets	164
Innovative formulations for drug delivery in cancer	165
Cancer targeting with polymeric drugs.....	165
<i>Linking anticancer drugs to polyglutamate</i>	166
<i>Improving delivery of protein-polymer anticancer drugs</i>	166
Macromolecules as delivery systems for taxanes.....	167
Polyamine conjugates as anticancer agents	167
Bacterial vectors as drug delivery systems for anticancer drugs	167
Nanoparticles as therapeutic delivery systems in cancer	168
<i>Subcutaneous injection of microspheres carrying anticancer drugs</i>	168
<i>Intravascular delivery systems using microparticles</i>	169
<i>Tumor embolization with drug-eluting beads</i>	169
<i>Tumor embolization with radioactive microparticles</i>	169
<i>Microparticles heated by magnetic field</i>	170
<i>Magnetic targeted microparticle technology</i>	170
<i>Release of drugs from biSphere by ultrasound</i>	170
<i>Release of drugs from micelles by ultrasound</i>	171
<i>Release of drugs from microcapsules by laser</i>	171
<i>Chemoembolization</i>	172
<i>Anticancer drugs bound to carbon particles</i>	172
<i>Anticancer drugs bound to protein microspheres</i>	172
<i>Nanoerythrocytes</i>	172
<i>Micronized droplets of olive oil</i>	172
Nanobiotechnology-based drug delivery for cancer	173
Nanoparticle formulations for drug delivery in cancer	174
<i>Anticancer drug particles incorporated in liposomes</i>	174
<i>Doxorubicin nanocarriers</i>	176
<i>Encapsulating drugs in hydrogel nanoparticles</i>	177

<i>Exosomes</i>	177
<i>Folate-linked nanoparticles</i>	178
<i>Lipid based nanocarriers</i>	178
<i>Micelles for drug delivery in cancer</i>	178
<i>Minicells for targeted delivery of nanoscale anticancer therapeutics</i>	180
<i>Nanobombs for cancer</i>	180
<i>Nanodiamonds for local delivery of chemotherapy at site of cancer</i>	181
<i>Nanoparticle formulation for enhancing anticancer efficacy of cisplatin</i>	181
<i>Nanoparticle formulations of paclitaxel</i>	182
<i>Nanoparticles containing albumin and antisense oligonucleotides</i>	182
<i>Nanotechnology-based non-invasive refilling of drug delivery depots</i>	182
<i>Non-aggregating nanoparticles</i>	183
<i>Pegylated nanoliposomal formulation</i>	183
<i>Perfluorocarbon nanoparticles</i>	183
<i>Protein nanocages for penetration of airway mucous and tumors</i>	183
<i>Protosphere nanoparticle technology</i>	184
Nanoparticles-based targeted delivery of therapeutics for cancer	184
<i>Antiangiogenic therapy using nanoparticles</i>	185
<i>Carbon magnetic nanoparticles for targeted drug delivery in cancer</i>	186
<i>Carbon nanotubes for targeted drug delivery to cancer cells</i>	186
<i>CRLX101 for targeted anticancer drug delivery</i>	187
<i>DNA aptamer-micelle for targeted drug delivery in cancer</i>	187
<i>Fullerenes for enhancing tumor targeting by antibodies</i>	187
<i>Gold nanoparticles for targeted drug delivery in cancer</i>	188
<i>Hepatic artery infusion of LDL-DHA nanoparticles for liver cancer</i>	189
<i>Iron oxide magnetic nanoparticle formulation for drug delivery</i>	189
<i>Lipoprotein nanoparticles targeted to cancer-associated receptors</i>	189
<i>Magnetic nanoparticles for remote-controlled drug delivery to tumors</i>	190
<i>Monitoring of targeted delivery by nanoparticle-peptide conjugates</i>	191
<i>Nanobees for targeted delivery of cytolytic peptide melittin</i>	191
<i>Nanocell for targeted drug delivery to tumor</i>	191
<i>Nanodroplets for site-specific cancer treatment</i>	192
<i>Nanogel-based stealth cancer vaccine targeting macrophages</i>	192
<i>Nanoparticle-mediated targeted delivery of peptides into tumors</i>	193
<i>Nanoparticle-mediated targeting of MAPK signaling pathway</i>	193
<i>Nanoparticles for targeted delivery of concurrent chemoradiation</i>	194
<i>Nanostructured hyaluronic acid for targeted drug delivery in cancer</i>	194
<i>Nanoparticles as antibody-drug conjugates</i>	194
<i>Nanoparticle-coated peptides for tumor targeting</i>	194
<i>Nanoparticle-mediated delivery of multiple anticancer agents</i>	195
<i>Polymer nanoparticles for targeted drug delivery in cancer</i>	195
<i>Polymersomes for targeted cancer drug delivery</i>	195
<i>Targeted drug delivery with nanoparticle-aptamer bioconjugates</i>	196
<i>Targeted nanoparticles delivery of cisplatin to mitochondrial genome</i>	197
<i>Time-delayed, dual-drug nanoparticle delivery system for cancer</i>	197
Dendrimers for anticancer drug delivery	198
<i>Application of dendrimers in boron neutron capture therapy</i>	198
<i>Application of dendrimers in photodynamic therapy</i>	199
<i>Dendrimer-based synthetic vector for targeted cancer gene therapy</i>	200
Devices for nanotechnology-based cancer therapy	200
<i>Convection-enhanced delivery with nanoliposomal CPT-11</i>	200
<i>Nanocomposite devices</i>	200
<i>Nanoengineered silicon for brachytherapy</i>	201
<i>Nanosensors for targeted drug delivery in cancer</i>	201
Nanoparticles combined with physical agents for tumor ablation	201
<i>Carbon nanotubes for laser-induced cancer destruction</i>	201
<i>Nanoparticles and thermal ablation</i>	202
<i>Nanoparticles combined with ultrasound radiation of tumors</i>	204
<i>Nanoparticles as adjuncts to photodynamic therapy of cancer</i>	204
<i>Nanoparticles for boron neutron capture therapy</i>	205
RNA nanotechnology for delivery of cancer therapeutics	205
Nanocarriers for simultaneous delivery of multiple anticancer agents.....	206
Combination delivery systems for nanoparticle penetration into tumor tissue	206
Combination of diagnostics and therapeutics for cancer	207
<i>Biomimetic nanoparticles targeted to tumors</i>	207
<i>Dendrimer nanoparticles for targeting and imaging tumors</i>	207
<i>Gold nanoparticle plus bombesin for imaging and therapy of cancer</i>	207
<i>Gold nanorods for diagnosis plus photothermal therapy of cancer</i>	207
<i>Magnetic nanoparticles for imaging as well as therapy of cancer</i>	208
<i>Nanobialys for combining MRI with delivery of anticancer agents</i>	208
<i>pHLIP nanotechnology for detection and targeted therapy of cancer</i>	209

<i>Polymer nanobubbles for targeted and controlled drug delivery</i>	209
<i>Radiolabeled carbon nanotubes for tumor imaging and targeting</i>	209
<i>Targeted therapy with magnetic nanomaterials guided by antibodies</i>	210
<i>Ultrasound tumor imaging and targeted chemotherapy by nanobubbles</i>	210
<i>Future prospects of nanobiotechnology and targeted cancer therapy</i>	210
Polyethylene glycol technology	211
Enzon's PEG technology	211
Debiopharm's PEG biconjugate drug delivery platform	211
Nektar PEGylation	212
PEG Intron	212
Single-chain antibody-binding protein technology	212
Vesicular systems for drug delivery in cancer	213
Liposomes for anticancer drug delivery	213
Antibody-targeted liposomes for cancer therapy	214
ALZA's Stealth liposomes	214
Boron-containing liposomes	215
DepoFoam technology	215
Hyperthermia and liposomal drug delivery	215
Liposomal doxorubicin formulation with N-octanoyl-glucosylceramide	216
Liposome-nucleic acid complexes for anticancer drug delivery	216
Non-pegylated liposomal doxorubicin	216
Tumor-selective targeted drug delivery via folate-PEG liposomes	216
Ultrasound-mediated anticancer drug release from liposomes	217
Companies developing liposome-based anticancer drugs	217
Pharmacosomes for controlled anticancer drug delivery	218
Emulsion formulations of anticancer drugs	219
Albumin-based drug carriers	219
Anticancer drugs that bind to tumors	219
Monoclonal T cell receptor technology	219
Radioactive materials for diagnosis and targeted therapy of cancer	220
Peptide receptor radionuclide therapy	220
Pretargeted radioimmunotherapy of cancer	220
Radiolabeled somatostatin receptor antagonists	221
Theophylline enhances radioiodide uptake by cancer	221
Strategies for drug delivery in cancer	221
Direct introduction of anticancer drugs into the tumor	222
<i>Injection into the tumor</i>	222
<i>Antineoplastic drug implants into tumors</i>	223
<i>Tumor necrosis therapy</i>	224
<i>Injection into the arterial blood supply of cancer</i>	224
<i>Electrochemotherapy</i>	226
<i>Pressure-induced filtration of drugs across vessels to the tumor</i>	226
Improving drug transport to tumors	226
<i>Carbohydrate-enhanced chemotherapy</i>	226
<i>Dextrans as macromolecular anticancer drug carriers</i>	227
<i>In situ production of anticancer agents in tumors</i>	227
<i>Iotophoresis for localized delivery of cancer chemotherapy</i>	227
Strategies for increasing drug penetration into solid cancers	228
Selective destruction of cancer cells	228
<i>Hyperbaric oxygen</i>	228
<i>Sphingolipids</i>	229
<i>Targeting response to transformation-induced oxidative stress</i>	229
<i>Targeting enzymes to prevent proliferation of cancer cells</i>	229
Targeted drug delivery in cancer	229
<i>Affibody molecules for targeted anticancer therapy</i>	230
<i>Fatty acids as targeting vectors</i>	230
<i>Genetic targeting of the kinase activity in cancer cells</i>	231
<i>Heat-activated targeted drug delivery</i>	231
<i>Novel transporters to target photosensitizers to cancer cell nuclei</i>	232
<i>Photodynamic therapy of cancer</i>	232
<i>Radionuclides delivered with receptor targeting technology</i>	233
<i>Targeting ligands specific for cancer cells</i>	233
<i>Targeting abnormal DNA in cancer cells</i>	234
<i>Targeted delivery by tumor-activated prodrug therapy</i>	234
<i>Targeting glutathione S-transferase</i>	236
<i>Targeting tumors by exploiting leaky blood vessels</i>	236
<i>Targeted drug delivery of anticancer agents with controlled activation</i>	237
<i>Targeted delivery of anticancer agents with ReCODE™ technology</i>	237
<i>Transmembrane Carrier Systems</i>	237
<i>Transferrin-oligomers as targeting carriers in anticancer drug delivery</i>	237
<i>Tumor targeting with peptides</i>	238

<i>Ultrasound and microbubbles for targeted anticancer drug delivery</i>	238
<i>Ultrasound for targeted delivery of chemotherapeutics</i>	239
<i>Vitamin B12 and folate for targeting cancer chemotherapy</i>	239
Cell-based drug delivery in cancer	241
<i>Red blood cells as vehicles for drug delivery</i>	241
<i>Cells as vehicles for gene delivery</i>	241
Drug delivery in relation to circadian rhythms	242
Implants for systemic delivery of anticancer drugs	243
<i>Drug-eluting polymer implants</i>	243
Angiogenesis and drug delivery to tumors	243
Antiangiogenesis strategies	244
<i>Targeting tumor endothelial cells</i>	244
<i>Methods for overcoming limitations of antiangiogenesis approaches</i>	245
Vascular targeting agents	246
<i>Alpha-emitting antibodies for vascular targeting</i>	246
<i>Angiolytic therapy</i>	246
<i>Anti-phosphatidylserine antibodies as VTA</i>	247
<i>Vadimezan</i>	247
<i>Cadherin inhibitors</i>	248
<i>Fosbretabulin tromethamine</i>	248
<i>Drugs to induce clotting in tumor vessels</i>	248
<i>Selective permeation of the anticancer agent into the tumor</i>	248
<i>Targeted delivery of tissue factor</i>	249
<i>Vascular targeting agents versus antiangiogenesis agents</i>	250
<i>ZD6126</i>	250
Delivery of proteins and peptides for cancer therapy	251
<i>CELLECTRA™ electroporation device</i>	251
<i>Emisphere's Eligen™ system</i>	252
<i>Diatos Peptide Vector intra-cellular/intra-nuclear delivery technology</i>	252
<i>Lytic peptides and cancer</i>	252
<i>Modification of proteins and peptides with polymers</i>	253
<i>Peptide-based targeting of cancer biomarkers for drug delivery</i>	253
<i>Peptide-cytokine complexes as vascular targeting agents</i>	254
<i>Peptide-polymer conjugates with radionuclides</i>	254
<i>Transduction of proteins in vivo</i>	254
<i>Tumor targeting by stable toxin (ST) peptides</i>	255
Image-guided personalized drug delivery in cancer	255
A computational approach to integration of drug delivery methods for cancer	255

4. Delivery of Biological Therapies for Cancer	256
Introduction	256
Antisense therapy	256
Basics of antisense approaches	256
Antisense cancer therapy	256
Mechanisms of anticancer effect of antisense oligonucleotides	257
Selected antisense drugs in development for cancer	257
<i>Antisense targeted to ribonucleotide reductase</i>	257
<i>Immune modulatory oligonucleotide</i>	258
Ribozyme therapy	258
Spiegelmers	259
Antisense drug delivery issues	259
Strategies to overcome delivery problems of antisense oligonucleotides	260
<i>Antisense delivery in microspheres</i>	260
<i>Delivery of antisense using nanoparticles</i>	260
<i>Delivery across the blood-brain barrier</i>	261
<i>Delivery of ribozymes</i>	261
<i>Iontophoretic delivery of oligonucleotides</i>	261
<i>Liposomes-mediated oligonucleotide delivery</i>	262
<i>Neugene™ antisense drugs</i>	262
<i>Oral delivery of oligonucleotides</i>	263
<i>Peptide nucleic acid delivery</i>	263
<i>Receptor-mediated endocytosis</i>	263
<i>Delivery of ribozymes</i>	264
Combination of antisense and electrochemotherapy	264
Aptamers for combined diagnosis and therapeutics of cancer	264
Antisense compounds in clinical trials	265
RNA interference	265
Basics of RNAi	265
Comparison of antisense and RNAi	266
RNAi applications in oncology	266
siRNA-based cancer immunotherapy	267

Delivery of siRNA in cancer	268
<i>Delivery of siRNA by nanoparticles</i>	268
<i>Delivery of siRNA by nanosize liposomes</i>	269
<i>Lipid nanoparticles for delivery of anticancer siRNAs</i>	270
<i>Polymer nanoparticles for targeted delivery of anticancer siRNA</i>	270
Lipophilic siRNA for targeted delivery to solid tumors.....	271
Companies developing cancer therapies based on antisense and RNAi	271
DNA interference	272
Cancer gene therapy	272
Basics of gene therapy	272
Strategies for cancer gene therapy.....	273
Gene transfer techniques as applied to cancer gene therapy.....	274
<i>Viral vectors</i>	274
<i>Nonviral vectors</i>	275
<i>A polymer approach to gene therapy for cancer</i>	275
Direct gene delivery to the tumor	276
<i>Injection into tumor</i>	276
<i>Reversible electroporation</i>	277
Hematopoietic gene transfer	278
<i>Genetic modification of human hematopoietic stem cells</i>	278
Gene-based strategies for immunotherapy of cancer (immunogene therapy).....	279
<i>Cytokine gene therapy</i>	279
Monoclonal antibody gene transfer	282
Transfer and expression of intracellular adhesion-1 molecules	283
Other gene therapy techniques for immunotherapy of cancer	283
<i>Chemokines</i>	283
<i>Engineered viruses as anticancer immunotherapy vectors</i>	284
<i>Fas (Apo-1)</i>	284
<i>IGF (Insulin-Like Growth Factor)</i>	284
<i>Major Histocompatibility Complex (MHC) Class I</i>	284
Inhibition of immunosuppressive function	284
microRNA gene therapy	285
Delivery of toxic genes to tumor cells for eradication (molecular chemotherapy).....	285
<i>Gene-directed enzyme prodrug therapy</i>	285
Combination of gene therapy with radiotherapy	286
Multipronged therapy of cancer with microencapsulated cells	287
Correction of genetic defects in cancer cells (mutation compensation)	287
Targeted gene therapy for cancer	288
<i>Transcriptional targeting for cancer gene therapy</i>	288
<i>Targeted epidermal growth factor-mediated DNA delivery</i>	288
<i>Gene-based targeted drug delivery to tumors</i>	288
<i>Targeting gene expression to hypoxic tumor cells</i>	289
<i>Targeting gene expression by progression-elevated gene-3 promoter</i>	289
<i>Targeted delivery of retroviral particles hitchhiking on T cells</i>	290
<i>Targeting tumors with genetically modified T cells</i>	290
<i>Targeting tumors by genetically engineered stem cells</i>	290
<i>Tumor-targeted gene therapy by receptor-mediated endocytosis</i>	291
<i>Targeted site-specific delivery of anticancer genes by nanoparticles</i>	291
<i>Immunolipoplex for delivery of p53 gene</i>	292
<i>Combination of electrogene and electrochemotherapy</i>	292
Virus-mediated oncolysis	292
<i>Targeted cancer treatments based on oncolytic viruses</i>	292
<i>Oncolytic gene therapy</i>	293
<i>Cancer terminator virus</i>	293
<i>Cytokine-induced killer cells for delivery of an oncolytic virus</i>	294
<i>Facilitating oncolysis by targeting innate antiviral response by HDIs</i>	294
<i>Oncolytic HSV</i>	295
<i>Oncolytic adenoviruses</i>	295
<i>Oncolytic Coxsackie virus A21</i>	297
<i>Oncolytic vesicular stomatitis virus</i>	297
<i>Oncolytic measles virus</i>	298
<i>Oncolytic paramyxovirus</i>	298
<i>Oncolytic reovirus</i>	298
<i>Oncolytic vaccinia virus</i>	299
<i>Synthetic oncolytic virus</i>	299
<i>Monitoring of viral-mediated oncolysis by PET</i>	299
<i>Companies developing oncolytic viruses</i>	300
Antiangiogenic therapy for cancer	300
Apoptotic approach to improve cancer gene therapy.....	301
Bacteria as novel anticancer gene vectors	302
Concluding remarks on cancer gene therapy	302

Cancer gene therapy companies	303
Cell therapy for cancer.....	305
Cellular immunotherapy for cancer.....	306
Treatments for cancer by ex vivo mobilization of immune cells	306
Granulocytes as anticancer agents	307
Neutrophil granulocytes in antibody-based immunotherapy of cancer	307
Use of hematopoietic stem cells for targeted cancer therapy	307
Cancer vaccines	308
Cell-based cancer vaccines.....	308
<i>Autologous tumor cell vaccines</i>	308
<i>Vaccines that simultaneously target different cancer antigens</i>	309
<i>Delivery systems for cell-based cancer vaccines</i>	309
<i>Intra-lymph node injections of cancer vaccine antigens</i>	310
Nucleic acid-based cancer vaccines	310
<i>Antiangiogenic DNA cancer vaccine</i>	310
<i>DNA cancer vaccines</i>	311
<i>Methods of delivery of DNA vaccines</i>	311
<i>RNA vaccines</i>	312
Viral vector-based cancer vaccines.....	312
Companies involved in nucleic acid-based vaccines	313
Genetically modified cancer cells vaccines.....	314
<i>GVAX cancer vaccines</i>	314
<i>Genetically modified dendritic cells</i>	315
Multipetide-based cancer vaccines.....	315

5. Delivery strategies according to cancer type and location 317

Introduction	317
Bladder cancer.....	317
Intravesical drug delivery.....	317
Intravesical agents combined with systemic chemotherapy	317
Targeted anticancer therapy for bladder cancer	318
Prodrug EOquin for bladder cancer	318
Antisense treatment of bladder cancer.....	319
Gene therapy for bladder cancer.....	319
Brain tumors.....	319
Methods for evaluation of anticancer drug penetration into brain tumor.....	320
Innovative methods of drug delivery for glioblastoma multiforme.....	320
Delivery of anticancer drugs across the blood-brain barrier	321
<i>Anticancer agents with increased penetration of BBB</i>	321
<i>BBB disruption</i>	322
<i>Nanoparticle-based targeted delivery of chemotherapy across the BBB</i>	322
<i>Tyrosine kinase inhibitor increases topotecan penetration into CNS</i>	324
Bypassing the BBB by alternative methods of drug delivery.....	324
<i>Intranasal perillyl alcohol</i>	324
<i>Intraarterial chemotherapy</i>	325
Enhancing tumor permeability to chemotherapy	325
Local delivery of chemotherapeutic agents into the tumor	326
<i>Carmustine biodegradable polymer implants</i>	326
<i>Fibrin glue implants containing anticancer drugs</i>	327
<i>Biodegradable microspheres containing 5-FU</i>	327
<i>Magnetically controlled microspheres</i>	327
Convection-enhanced delivery	327
<i>CED for receptor-directed cytotoxin therapy</i>	327
<i>CED of topotecan</i>	328
<i>CED of a modified diphtheria toxin conjugated to transferrin</i>	328
<i>CED of nanoliposomal CPT-11</i>	329
<i>CED for delivery ¹³¹I-chTNT-1/B MAb</i>	329
Anticancer drug formulations for targeted delivery to brain tumors	329
<i>Intravenous delivery of anticancer agents bearing transferrin</i>	329
<i>Liposomes for drug delivery to brain tumors</i>	329
<i>MABs targeted to brain tumors</i>	330
<i>Multiple targeted drugs for brain tumors</i>	330
<i>Nanoparticles for targeted drug delivery in glioblastoma multiforme</i>	331
<i>Targeted antiangiogenic/apoptotic/cytotoxic therapies</i>	332
Introduction of the chemotherapeutic agent into the CSF pathways.....	333
<i>Intraventricular chemotherapy for meningeal cancer</i>	333
<i>Intrathecal chemotherapy</i>	334
Interstitial delivery of dexamethasone for reduction of peritumor edema	334
Combination of chemotherapy with radiotherapy	334
Photodynamic therapy for chemosensitization of brain tumors	335
<i>Nanoparticles for photodynamic therapy of brain tumors</i>	335

Innovative delivery of radiotherapy to brain tumors	335
<i>GliaSite Radiation Therapy System</i>	335
<i>Boron neutron capture therapy for brain tumors</i>	336
Cell therapy for glioblastoma multiforme	336
<i>Chimeric antigen receptor T cells</i>	336
<i>Mesenchymal stem cells to deliver treatment for gliomas</i>	336
<i>Stem cell-based therapy targeting EGFR in GBM</i>	337
Gene therapy for glioblastoma multiforme	337
<i>Antiangiogenic gene therapy</i>	338
<i>Anticancer drug delivery by genetically engineered MSCs</i>	339
<i>Gene transfer to brain tumor across the BBB by nanobiotechnology</i>	339
<i>Intravenous gene delivery with nanoparticles into brain tumors</i>	339
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i>	339
<i>Neural stem cells for drug/gene delivery to brain tumors</i>	340
<i>Peptides targeted to glial tumor cells</i>	341
<i>RNAi gene therapy of brain cancer</i>	341
<i>Single-chain antibody-targeted adenoviral vectors</i>	341
<i>Targeting normal brain cells with an AAV vector encoding interferon-β</i>	342
<i>Treatment of medulloblastoma by suppressing genes in Shh pathway</i>	342
<i>Virus-mediated oncolytic therapy of glioblastoma multiforme</i>	342
Vaccination for glioblastoma multiforme	345
<i>Cell-based vaccines for GBM</i>	345
<i>Peptide vaccines for GBM</i>	345
<i>Oncolytic viral delivery by stem cells for brain metastases of melanoma</i>	346
Breast Cancer	346
Therapies for breast cancer involving innovative methods of drug delivery	347
Injectable biodegradable polymer delivery system for local chemotherapy	347
MammoSite brachytherapy	347
Monoclonal antibodies targeted to HER2 receptor	348
Breast cancer vaccines	348
<i>HER-2 DNA AutoVac™ vaccine</i>	349
<i>Recombinant adenoviral ErbB-2/neu vaccine</i>	349
<i>Gene vaccine for breast cancer</i>	350
<i>NeuVax</i>	350
Gene therapy for breast cancer	351
Antisense therapy for breast cancer	351
Inhibitors of growth factors FGF2 and VEGF for breast cancer	352
Targeted multi-drug delivery approach to breast cancer	352
Cancer of the cervix and the uterus	352
Gene therapy for cervical cancer	352
Delivery of chemoradiation therapy	353
Cervical cancer vaccines	353
Cancer of the liver	353
Hepatocellular carcinoma	353
Treatment of liver metastases	355
Gastrointestinal cancer	355
Colorectal cancer	355
<i>Oxaliplatin long-circulating liposomes</i>	355
<i>Perifosine</i>	355
<i>Targeted delivery of triple anticancer therapy by local patch</i>	356
Gastrointestinal stromal tumor	356
Vaccines for gastrointestinal cancer	356
Hematological malignancies	357
Leukemia	357
<i>Clofarabine</i>	358
<i>Ibrutinib</i>	358
<i>Idelalisib for CLL</i>	358
Multiple myeloma	358
<i>Monoclonal antibody therapy in multiple myeloma</i>	358
Non-Hodgkin's lymphoma	359
<i>Idelalisib for NHL</i>	359
<i>Pixantrone</i>	359
Malignant melanoma	360
Targeted therapies for melanoma	360
Immunotherapy for malignant melanoma	361
Gene therapy for malignant melanoma	361
Nasopharyngeal carcinoma	363
Synergistic effect of gene therapy with 5-FU	363
Neuroblastoma	364
Genetically modified NSCs for treatment of neuroblastoma	364
Non-small cell lung cancer	364

Aerosol delivery of anticancer agents for lung cancer.....	366
Aerosol gene delivery for lung cancer	366
Complex nanoscale pulmonary delivery of drugs for resistant lung cancer.....	367
Intratumoral administration of anticancer drugs through a bronchoscope.....	367
Ovarian cancer.....	367
Innovative drug delivery for ovarian cancer.....	367
Intravenous ascorbate for ovarian cancer.....	368
Intraperitoneal delivery	368
Modulation of protein ubiquitination	369
Targeting Notch pathway to overcome resistance to chemotherapy	369
Dendritic cell vaccination for ovarian cancer	370
Gene Therapy for ovarian cancer	370
Pancreatic cancer	371
Delivery of chemotherapy for pancreatic cancer	371
<i>Local drug delivery.....</i>	<i>371</i>
<i>Localized drug delivery by iontophoresis</i>	<i>371</i>
<i>Nanoparticle-based delivery of tumor-penetrating peptides</i>	<i>372</i>
<i>Targeted chemotherapy for pancreatic cancer.....</i>	<i>372</i>
<i>Transport properties of pancreatic cancer and gemcitabine delivery</i>	<i>372</i>
Vaccine for pancreatic cancer	373
Gene therapy for pancreatic cancer	373
<i>Correction of altered genes</i>	<i>373</i>
<i>Targeted gene therapy</i>	<i>374</i>
<i>Targeting in pancreatic adenocarcinoma with cell surface antigens.....</i>	<i>374</i>
<i>Targeted Expression of BikDD gene.....</i>	<i>374</i>
<i>Viral oncolysis in pancreatic cancer</i>	<i>374</i>
Prostate cancer.....	375
Alpha emitter radium-223 for targeting bone metastases in cancer	376
Brachytherapy for cancer of prostate.....	376
<i>Brachytherapy via paravertebral approach lymph node metastases.....</i>	<i>376</i>
Capridine-beta.....	376
LHRH for prostate cancer	377
<i>LHRH analogs.....</i>	<i>377</i>
<i>Histrelin implant</i>	<i>377</i>
Immunomodulatory drugs.....	377
MAbs for prostate cancer	378
PACLIMER Microspheres.....	378
PRX302	379
Targeted therapies for prostate cancer	379
<i>Delivery of cisplatin to prostate cancer by nanoparticles</i>	<i>379</i>
<i>Delivery of siRNAs to prostate cancer with aptamer-siRNA chimeras.....</i>	<i>379</i>
<i>Delivery of siRNA for prostate cancer with metastases.....</i>	<i>379</i>
<i>Gold nanoparticles targeted to laminin receptor in prostate cancer.....</i>	<i>380</i>
<i>PSA-activated protoxin that kills prostate cancer.....</i>	<i>380</i>
<i>Targeted drug delivery with nanoparticle-aptamer bioconjugates</i>	<i>380</i>
<i>Targeted delivery of a nanoparticulate platinum prodrug.....</i>	<i>381</i>
<i>Targeting oncogene MDM2 in prostate cancer.....</i>	<i>381</i>
<i>Vascular targeting of prostate cancer</i>	<i>381</i>
Gene therapy for cancer of prostate	382
<i>Experimental studies</i>	<i>382</i>
<i>Nanoparticle-based gene therapy for prostate cancer.....</i>	<i>382</i>
<i>Tumor suppressor gene therapy in prostate cancer</i>	<i>382</i>
<i>Vaccines for prostate cancer.....</i>	<i>383</i>
<i>Clinical trials of gene therapy for prostate cancer.....</i>	<i>383</i>
Viral oncolysis for prostate cancer	384
Combined approaches	385
Combined autovaccination and hyperthermia	385
Thyroid cancer	385
6. Cancer drug delivery markets.....	387
Introduction	387
Global markets for drug delivery.....	387
Estimation of cancer drug delivery markets.....	387
<i>Methods used for market estimation.....</i>	<i>387</i>
<i>Cancer epidemiology</i>	<i>388</i>
<i>Cost of patient care in cancer</i>	<i>390</i>
Market forecasts 2016-2026.....	390
Cancer drug market	390
<i>Market for leukemia</i>	<i>391</i>
<i>Market for lymphoma</i>	<i>391</i>
<i>Markets for brain tumors</i>	<i>392</i>

Market for breast cancer.....	392
Market for ovarian cancer	392
Geographical distribution of cancer markets	392
Factors affecting future cancer markets	392
Market share according to cancer drug delivery technologies.....	393
Antiangiogenesis therapies.....	394
Antibody drug conjugates	394
Antineoplastic drug implants for systemic administration	394
Antisense therapy and RNAi	394
Cancer vaccines.....	395
Cell/gene therapy	395
Liposomes for anticancer drugs	395
Monoclonal antibodies	395
Modulators of protein ubiquitination	396
Strategic aspects of cancer drug delivery	396
Unmet needs in cancer drug delivery.....	396
Future of cancer drug delivery.....	397
Cancer drug delivery and pharmacogenomics	397
Cancer immunotherapy markets	398
Drug delivery for cancer in the postgenomic era	398
Role of nanobiotechnology in development of cancer drug delivery markets	398
Expansion of cancer drug delivery markets in developing countries	398
Drivers for the development of drug delivery technologies in cancer.....	398

7. References..... 401

Tables

Table 1-1: Estimated new cases of cancer in the US at most involved organs – 2012	42
Table 1-2: Historical landmarks in drug delivery for cancer	46
Table 2-1: Innovative strategies against cancer.....	47
Table 2-2: A classification of antiangiogenic therapies	50
Table 2-3: Selected antiangiogenic agents in development for cancer.....	56
Table 2-4: Approaches to cancer therapy based on bacteria.....	58
Table 2-5: Cell therapy technologies used for cancer.....	66
Table 2-6: Non-nucleic acid cancer vaccines without genetic modification	71
Table 2-7: Monoclonal antibodies for cancer approved by the FDA	83
Table 2-8: Anticancer agents linked to monoclonal antibodies	87
Table 2-9: Monoclonal antibodies in clinical trials for cancer	91
Table 2-10: Antibody drug conjugates in clinical trials for cancer	97
Table 2-11: Third generation boron delivery agents currently under investigation	101
Table 2-12: Cellular pathways as targets for anticancer therapies.....	109
Table 2-13: Examples of anticancer agents that target mitochondrial membranes.....	110
Table 2-14: Drugs targeting oncogenes	114
Table 2-15: PARP inhibitors for cancer therapy	136
Table 2-16: Cancer therapies based on the P53	141
Table 2-17: Promise of personalized therapy in cancer	146
Table 2-18: Companies developing personalized therapy for cancer	146
Table 3-1: Routes of drug delivery in cancer	153
Table 3-2: Systemic intravenous drug delivery systems for chemotherapy of cancer	153
Table 3-3: Approved oral chemotherapy drugs	155
Table 3-4: Microparticles as therapeutic delivery systems in cancer	168
Table 3-5: Classification of nanobiotechnology approaches to drug delivery in cancer.....	173
Table 3-6: Approved anticancer drugs using nanocarriers	174
Table 3-7: Clinical trials of anticancer drugs using nanocarriers	174
Table 3-8: Marketed preparations for liposome-based anticancer drugs	217
Table 3-9: Clinical trials of liposome-based anticancer drugs.....	217
Table 3-10: Strategies for drug delivery in cancer.....	221
Table 3-11: Implant systems for delivery of anticancer drugs into tumors.....	223
Table 3-12: Methods of delivery of antiangiogenesis therapies.....	244
Table 3-13: Companies developing vascular targeting agents.....	246
Table 4-1: Mechanisms of anticancer effect of antisense oligonucleotides	257
Table 4-2: Methods of delivery of oligonucleotides for cancer therapy	259
Table 4-3: Antisense oligonucleotides in clinical trials for cancer	265
Table 4-4: Companies developing antisense and RNAi therapies for cancer	271
Table 4-5: Strategies for cancer gene therapy	273
Table 4-6: Enzyme/prodrug combinations employed in suicide gene therapy.....	286
Table 4-7: Mutation compensation strategies used clinically	287
Table 4-8: Companies developing oncolytic viruses	300
Table 4-9: Companies involved in cancer gene therapy	303

Table 4-10: Cell therapy technologies used for cancer	305
Table 4-11: Companies developing nucleic acids/genetically modified cells-based cancer vaccines	313
Table 5-1: Innovative methods of drug delivery for glioblastoma multiforme	320
Table 5-2: Strategies for gene therapy of malignant brain tumors.....	337
Table 5-3: Clinical trials of oncolytic virotherapy against glioblastoma multiforme.....	344
Table 5-4: Therapies for breast cancer involving innovative methods of drug delivery	347
Table 5-5: Drug delivery for hepatocellular carcinoma	353
Table 5-6: Gene therapy for malignant melanoma	362
Table 5-7: Targeted treatment of non-small cell lung cancer	365
Table 5-8: Clinical trials of gene therapy in ovarian cancer.....	370
Table 5-9: Methods of drug delivery in pancreatic cancer.....	371
Table 5-10: Pharmacological strategies under investigation for cancer of the prostate	375
Table 5-11: Clinical trials of gene therapy for prostate cancer	384
Table 6-1: Worldwide drug delivery market growth 2016 to 2026	387
Table 6-2: Worldwide prevalence of cancer according to type of cancer 2015-2025.....	388
Table 6-3: Estimated number of cancer patients in major markets 2016-2026	389
Table 6-4: Worldwide anticancer drug sales for selected cancers from 2016 to 2026	391
Table 6-5: Geographical distribution of cancer markets 2016-2026	392
Table 6-6: Market values of cancer drug delivery technologies from 2016-2026.....	393

Figures

Figure 1-1: Structure of PD-1 pathway	23
Figure 1-2: An overview of some key steps in tumor angiogenesis.	38
Figure 2-1: Targeting tumors with light-emitting engineered bacteria.....	60
Figure 2-2: Enhancing tumor-cell visibility to the immune system by viral mimicry	70
Figure 2-3: Schematic role of T helper cells in immune response to cancer	75
Figure 2-4: Antimetabolic anticancer effect of SR9243 by inhibiting Warburg effect.....	140
Figure 3-1: Cyclacel's Penetratin Transport System for delivery of drugs to targets.....	165
Figure 3-2: Micelle for drug delivery in cancer	179
Figure 3-3: Mechanism of action of Targaceutical drugs.....	231
Figure 3-4: VIADUR leuprolide acetate using DUROS implant technology	243
Figure 5-1: A concept of targeted drug delivery to GBM across the BBB.....	323
Figure 6-1: Unmet needs in cancer drug delivery	397